Aviva Holdings Ltd. Macrogenics Inc Transaction History

Aviva Holdings Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$11.11 - $25.6 $42,384 - $97,664	-3,815 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$11.75 - $21.42 $7.77 Million - $14.2 Million	-660,970 Reduced 99.43%	3,815 $48,000
Q3 2018 Nov 14, 2018	SELL	$19.26 - $23.46 $6.02 Million - $7.33 Million	-312,641 Reduced 31.99%	664,785 $14.3 Million
Q1 2018 May 15, 2018	BUY	$18.89 - $32.46 $3.59 Million - $6.17 Million	190,166 Added 24.16%	977,426 $24.6 Million
Q4 2017 Feb 14, 2018	BUY	$16.19 - $20.3 $10.9 Million - $13.6 Million	671,346 Added 579.18%	787,260 $15 Million
Q3 2017 Nov 14, 2017	BUY	$15.52 - $18.94 $1.8 Million - $2.2 Million	115,914	115,914 $0

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Aviva Holdings Ltd., based on Form 13F filings with the SEC.

Stay updated on Aviva Holdings Ltd. with notifications on news.